Company intelligence / Profile preview

Oxford BioDynamics

Overview

Oxford BioDynamics has two commercialized blood-based diagnostic tests:

EpiSwitch® PSE for highly accurate prostate cancer detection—improves PSA test accuracy from 55% to 94%.
EpiSwitch® CiRT predicts patient response to immuno-oncology checkpoint inhibitor therapies with ~85% accuracy. The company’s proprietary platform enables rapid biomarker discovery and test development across oncology and other diseases. Additional pipeline programs target colorectal cancer screening and various neurological/inflammatory conditions

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Blood-based diagnostic tests (using 3D genomic biomarkers)Molecular diagnostics
Industry: Molecular Diagnostics

2 assets

Commercial

1 more asset in the full pipeline.

PfizerEMD SeronoGenentech/RocheBiogenMayo ClinicMassachusetts General HospitalMitsubishi Tanabe Pharma

Beyond the preview

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Follow clinical development from trial design and recruitment through results.

Explore licensing agreements, acquisitions, and the assets behind each deal.

Trace financing activity and the investors behind a company’s development.

Compare peer pipelines by target, modality, and therapeutic area.

Explore technology platforms and the patent landscape around relevant assets.

Connect company news and source material to the questions you’re investigating.

See how Gosset can support your research on Oxford BioDynamics.